Preparation and evaluation of schisandrin B-loaded F127 modified lipid-polymer nanoparticles for inhibition of breast cancer lung metastasis.
10.19540/j.cnki.cjcmm.20200819.305
- Author:
Fei YAN
1
;
Jiang-Pei SHI
1
;
Hai-Zhen CHEN
1
;
Jun-Yi SHEN
1
;
Xing-Mei XIE
1
;
Zi-Fei JIANG
1
;
G U XIAO-YAN
1
;
Ying LIU
1
;
Nian-Ping FENG
1
Author Information
1. School of Pharmacy, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
F127 modified lipid-polymer nanoparticles;
TGF-β1;
bioa-vailability;
breast cancer lung metastasis;
oral administration;
schisandrin B
- MeSH:
Animals;
Cyclooctanes;
Lignans;
Lipids;
Lung Neoplasms/drug therapy*;
Mice;
Nanoparticles;
Polycyclic Compounds;
Polyethylenes;
Polymers;
Polypropylenes;
Rats;
Swine
- From:
China Journal of Chinese Materia Medica
2020;45(21):5177-5183
- CountryChina
- Language:Chinese
-
Abstract:
In the current study, schisandrin B(SchB)-loaded F127 modified lipid-polymer hybrid nanoparticles(SchB-F-LPNs) were developed to improve the inhibition of breast cancer lung metastasis. Modified nanoprecipitation method was used to prepare SchB-F-LPNs. The nanoparticles were spherical in shape with shell-core structure by TEM observation. SchB-F-LPNs showed a mean particle size of(234.60±6.11) nm with zeta potential of(-5.88±0.49) mV. XRD results indicated that SchB existed in the nanoparticles in an amorphous state. The apparent permeability coefficient through porcine mucus of F-LPNs was 1.43-fold of that of LPNs as shown in the in vitro mucus penetration study. The pharmacokinetics study showed that the C_(max) of SchB was(369.06±146.94) μg·L~(-1),(1 121.34±91.65) μg·L~(-1) and(2 951.91±360.53) μg·L~(-1) respectively in SchB suspensions group, SchB-LPNs group and SchB-F-LPNs group after oral administration in rats. With SchB suspensions as the reference formulation, the relative bioavailability of SchB-F-LPNs was 568.60%. SchB-F-LPNs inhibited the morphological change during transforming growth factor-β1(TGF-β1)-induced epithelial-mesenchymal transition. In addition, SchB-F-LPNs significantly decreased the number of metastatic pulmonary nodules in 4 T1 tumor-bearing mice, suggesting that SchB-F-LPNs may inhibit the metastasis of breast cancer. These results reveal the promising potential of SchB-F-LPNs in treatment of breast cancer lung metastasis.
